Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch
- 22 June 2019
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 37 (31), 4243-4245
- https://doi.org/10.1016/j.vaccine.2019.06.021
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as ToddlersThe Pediatric Infectious Disease Journal, 2019
- Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccineVaccine, 2019
- Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2018
- Improving vaccine coverage in adolescence and beyondHuman Vaccines & Immunotherapeutics, 2017
- Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, CanadaClinical Infectious Diseases, 2017
- Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort studyThe Lancet, 2016
- Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)Vaccine, 2013
- The Changing Epidemiology of Meningococcal Disease in Quebec, Canada, 1991–2011: Potential Implications of Emergence of New StrainsPLOS ONE, 2012
- Meningococcal carriage by age: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2010
- Invasive Meningococcal Disease in Québec, Canada, Due to an Emerging Clone of ST-269 Serogroup B Meningococci with Serotype Antigen 17 and Serosubtype Antigen P1.19 (B:17:P1.19)Journal of Clinical Microbiology, 2006